PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063. The data were presented today at the 8^th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS) in Munich, Germany. TSIS is a medical conference which focuses on the latest knowledge, developments and innovative concepts related to the recognition of disease as well as patient care and therapy within the wide field of acute and chronic systemic inflammation.

“An Approach to New Antibiotics for Avoiding Resistance: PMX-30063”

PolyMedix’s Vice President of Clinical Development and Chief Medical Officer, Dr. Eric McAllister, presented during a session that focused on the problem of bacterial drug resistance to antibiotics, superbugs and the need for new antibiotic drugs. His presentation entitled, “An Approach to New Antibiotics for Avoiding Resistance: PMX-30063”, described the results to date from the Phase 1B dose-escalation clinical study which showed that the administration of multiple doses of PMX-30063 is safe and well-tolerated, with no clinically significant adverse effects at potential therapeutic dose levels. Dr. McAllister also presented data showing that PMX-30063 kills Staph bacteria, including MRSA, in human serum in blood samples drawn from study subjects at these same potential therapeutic dose levels.

PolyMedix’s novel antibiotic compound, PMX-30063, is a small molecule mimetic of human host-defense proteins, one of the oldest and most effective antimicrobial defense systems found in virtually all living creatures. PMX-30063 has unique properties including a mechanism of action that is completely different from current antibiotic drugs. PMX-30063 directly disrupts the bacterial cell membrane, which is intended to make bacterial resistance unlikely to develop. In addition, it is fast acting and kills bacteria directly (bactericidal) rather than simply stopping bacterial reproduction (bacteriostatic, like many other antibiotic drugs). PMX-30063 is believed to be the first antibiotic with this mechanism of action being developed for use in systemic infections.